Securing and Qualifying Single-Use Technologies - The authors suggest techniques for mitigating risk and securing the supply chain for single-use components used in biopharmaceutical manufacturing. -

ADVERTISEMENT

Securing and Qualifying Single-Use Technologies
The authors suggest techniques for mitigating risk and securing the supply chain for single-use components used in biopharmaceutical manufacturing.


BioPharm International Supplements
Volume 26, Issue 4, pp. s18-s23

CONCLUSION

Single-use technologies will continue to be adopted over the next decade within the biopharmaceutical industry in an ever-expanding capacity (4). Establishing controls and processes that follow an ICH Q10 risk-based approach is one suggested methodology to help establish best practices and controls for introduction and security of these single-use technologies.

With the movement of the industry towards single-use components, many companies have started to address the impact of single-use equipment on product quality. The use of risk analysis is a powerful tool for implementing a single-use program.

KEVIN D. LEAR is a Principal Engineer, NICOLE COLLIER is Engineer III, and KEITH BADER is Sr. Director of Technology, all at Hyde Engineering + Consulting, Inc, Boulder, CO.

REFERENCES

1. BioSolve Software Modeling, BioPharm Services, Chesham, Buckingham, HP5 1DG, UK, http://www.biopharmservices.com/.

2. Intelligen Software Services, Intelligen, Scotch Plains, NJ 07076 USA, http://www.intelligen.com/.

3. ICH, Q10, Pharmaceutical Quality System (2008).

4. Single Use Bioreactors for Pharma; World Market 2012-2022, Vision Gain http://www.visiongain.com/.

5. Martin, J. BioPharm Inter., 23 (11)(2010).

6. ICH, Q9 Quality Risk management (2005).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here